Skip to main content
Premium Trial:

Request an Annual Quote

New York Issues Clinical Laboratory Permit to Genetic Technologies

NEW YORK (GenomeWeb News) – Genetic Technologies today said that New York has issued a Clinical Laboratory Permit to the firm, allowing GTG to offer its BREVAGen test to residents of the state.

The permit completes the out-of-state licensures needed, and GTG can offer the breast cancer test to all 50 states in the US. GTG received CLIA certification of compliance for its Australian lab in February 2012.

Its wholly owned subsidiary Phenogen Sciences will soon appoint representatives to cover New York, with a particular emphasis on New York City, GTG said.

Earlier this week, the company said it received additional commitments for a private placement to raise A$800,000 and increased the level of underwriting on its current share purchase plan to A$1.8 million.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.